168 related articles for article (PubMed ID: 19369675)
1. Risks of long-acting beta-agonists in achieving asthma control.
Drazen JM; O'Byrne PM
N Engl J Med; 2009 Apr; 360(16):1671-2. PubMed ID: 19369675
[No Abstract] [Full Text] [Related]
2. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.
Kramer JM
N Engl J Med; 2009 Apr; 360(16):1592-5. PubMed ID: 19369665
[No Abstract] [Full Text] [Related]
3. Part IV: Genetic variations in beta2-adrenergic receptors: long-acting and short-acting beta2-agonists and therapeutic response.
Peters S
Curr Med Res Opin; 2007 Sep; 23 Suppl 3():S29-36. PubMed ID: 17925066
[TBL] [Abstract][Full Text] [Related]
4. Long-acting beta-agonists in asthma.
Knobil K
N Engl J Med; 2009 Jul; 361(2):208-9; author reply 209. PubMed ID: 19593857
[No Abstract] [Full Text] [Related]
5. Beta-adrenergic bronchodilators.
Nelson HS
N Engl J Med; 1995 Aug; 333(8):499-506. PubMed ID: 7623883
[No Abstract] [Full Text] [Related]
6. [Beta 2-sympathomimetic drugs].
Criée CP; Laier-Groeneveld G
Internist (Berl); 1995 Sep; 36(9):918-23. PubMed ID: 7591618
[No Abstract] [Full Text] [Related]
7. Salmeterol and paroxetine: more evidence for paradoxical medicine.
Yun AJ; Lee PY; Doux JD
Med Hypotheses; 2006; 66(5):1037-8. PubMed ID: 16364562
[No Abstract] [Full Text] [Related]
8. Beta 2-agonist bronchodilators--advances versus controversies.
O'Donnell SR
Proc West Pharmacol Soc; 1993; 36():323-7. PubMed ID: 8104346
[No Abstract] [Full Text] [Related]
9. Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.
Kim D; Glaum M; Lockey R
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):933-40. PubMed ID: 19619072
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol for the treatment of asthma.
Weinberger M
Ann Allergy Asthma Immunol; 1995 Sep; 75(3):209-11. PubMed ID: 7552921
[No Abstract] [Full Text] [Related]
11. beta-Adrenergic bronchodilators and sudden death in asthmatics.
Drug Ther Bull; 1976 Mar; 14(6):21-2. PubMed ID: 6237
[No Abstract] [Full Text] [Related]
12. [beta2-Sympathomimetics: dangers in asthma therapy? Lessons from the SMART1 Study].
Riedl-Seifert R
Dtsch Med Wochenschr; 2007 Mar; 132(12):633; author reply 633-4. PubMed ID: 17357910
[No Abstract] [Full Text] [Related]
13. Salmeterol.
Med Lett Drugs Ther; 1994 Apr; 36(921):37-9. PubMed ID: 7909139
[No Abstract] [Full Text] [Related]
14. The FDA and safe use of long-acting beta-agonists in the treatment of asthma.
Chowdhury BA; Dal Pan G
N Engl J Med; 2010 Apr; 362(13):1169-71. PubMed ID: 20181964
[No Abstract] [Full Text] [Related]
15. Beta-agonists--friends or foes?
Staudinger HW; Haas JF
Eur Respir J; 1992 Jul; 5(7):894-5, author reply 898-900. PubMed ID: 1354170
[No Abstract] [Full Text] [Related]
16. Study designs of adverse events in asthma treatment.
Ernst P; Suissa S
Eur Respir J; 1992 Jul; 5(7):773-5. PubMed ID: 1354169
[No Abstract] [Full Text] [Related]
17. Is there a problem with inhaled long-acting beta-adrenergic agonists?
Nelson HS
J Allergy Clin Immunol; 2006 Jan; 117(1):3-16; quiz 17. PubMed ID: 16387577
[TBL] [Abstract][Full Text] [Related]
18. [The therapeutic potentials of Berotec-100 in bronchial asthma patients].
Emel'ianov AV; Shevelev SE; Shubin SA; Sinitsina TM; Fedoseev GB
Klin Med (Mosk); 1998; 76(7):38-9. PubMed ID: 9742777
[No Abstract] [Full Text] [Related]
19. Long-acting bronchodilators for the control of asthma symptoms.
Marshall GD
Ann Allergy Asthma Immunol; 2001 Jan; 86(1):3-4. PubMed ID: 11206235
[No Abstract] [Full Text] [Related]
20. Regular beta-agonist therapy--the quality of the evidence.
Sears MR; Taylor DR
Eur Respir J; 1992 Jul; 5(7):896-7, author reply 898-900. PubMed ID: 1354171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
